clinical trial

[EpicentRx, Inc.] EpicentRx, Inc., a clinical-stage biotechnology company at the forefront of oncolytic viruses and small molecules for the treatment of cancer and other inflammatory-driven diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,906,957 entitled "Immunomodulatory Fusion Proteins."

[Eloxx Pharmaceuticals, Inc.] Eloxx Pharmaceuticals, Inc. announced positive topline results from the monotherapy arms of its Phase II clinical trial of ELX-02 in Class 1 cystic fibrosis patients with at least one G542X nonsense allele mutation.

[Biosplice Therapeutics, Inc.] Biosplice Therapeutics, Inc. announced the dosing of the first subject in a Phase Ib, open-label, multicenter, dose-escalation, dose expansion clinical trial of cirtuvivint in subjects with advanced solid tumors.

[Pulmonem, Inc.] Pulmonem, Inc. and the Research Institute of the McGill University Health Centre today announced that they have successfully started recruiting US-based patients for the Phase III Clinical Trial of the promising COVID-19 therapeutic drug PULM-001.

[Apollomics, Inc.] Apollomics, Inc. announced that the first patient has been successfully dosed in a Phase III clinical trial of APL-106 for the treatment of adults with relapsed or refractory acute myeloid leukemia in China.

[Graphite Bio, Inc.] Graphite Bio, Inc. announced that the first patient has been enrolled in the company’s Phase I/II clinical trial of GPH101, an investigational gene-edited autologous hematopoietic stem cell therapy designed to directly correct the genetic mutation that causes sickle cell disease.